Biogen Inc.
Market Data Current As Of: September 12, 2026
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore Biogen
Core profile pages, annual revenue records, and related research hubs for this company.
Biogen Inc.
Compare market positioning with top industry peers
Explore Biogen
Core profile pages, annual revenue records, and related research hubs for this company.
Company History
Founded 1978 in Cambridge, Massachusetts
Geneva, 1978. Phillip Sharp of MIT, Walter Gilbert of Harvard, and Charles Weissmann of the University of Zurich — three of the most prominent molecular biologists in the world — co-founded a research company to explore whether recombinant DNA technology could be translated into commercial medicines. The founding scientific team was extraordinary even by biotechnology standards; both Sharp and Gilbert would subsequently receive Nobel Prizes for work unrelated to Biogen, which says something about the caliber of scientific judgment the company was built on. The early years focused on interferon — a protein that appeared to have antiviral and potentially anticancer properties — before the field pivoted toward understanding which proteins the human immune system produced in disease states and whether synthetic versions could treat those diseases. Multiple sclerosis emerged as the primary focus because the immune system dysregulation that characterizes MS was accessible to biological therapy in ways that neurodegenerative diseases were not. Avonex, a form of interferon beta-1a, received FDA approval in 1991 for relapsing forms of multiple sclerosis. It was the first effective biological treatment for MS and transformed Biogen from a research-stage company into a commercial pharmaceutical enterprise. The drug generated billions in annual revenue at its peak and funded the research infrastructure that produced subsequent neurological assets. The 2003 approval of Tysabri, an antibody that reduced MS relapse rates more than interferon-based therapies, initially appeared to be the next breakthrough — until post-market surveillance identified a rare but fatal brain infection called PML as a side effect. The FDA mandated a risk mitigation program that required specialized monitoring and restricted prescribing. Tysabri survived as a treatment for patients with aggressive MS who accepted the PML risk, but its commercial trajectory was permanently constrained.
Biogen is one of the foundational pillars of the global biotechnology industry, founded in 1978 in Geneva, Switzerland, by a syndicate of some of the most brilliant and decorated scientists in human history. The founding group included two future Nobel Laureates: Walter Gilbert (a molecular biologist at Harvard who won the Nobel Prize in Chemistry for developing a method to sequence DNA) and Phillip Sharp (a biologist at MIT who won the Nobel Prize in Medicine for his discovery of split genes). They were brought together by a brilliant venture capitalist named Kevin Kinsella and a seasoned pharmaceutical executive named Ray Schaefer. The founding of Biogen (which originally stood for 'Biotechnology Geneva') occurred precisely at the dawn of the recombinant DNA revolution. While its rival Genentech was focused on synthesizing human insulin, Biogen's founders were obsessed with interferon—a naturally occurring protein that scientists believed could be a miraculous cure for cancer and viral infections. In 1980, Charles Weissmann, one of Biogen's founding scientists, achieved a breakthrough by cloning leukocyte interferon alpha. This proved that a small biotech startup could outmaneuver the R&D budgets of legacy pharmaceutical giants. The company subsequently moved its headquarters to Cambridge, Massachusetts, anchoring what would become Kendall Square, the most densely concentrated biotechnology hub on Earth. While interferon ultimately proved to be a failure as an universal cancer cure, the deep, world-class scientific rigor established by Gilbert, Sharp, and Weissmann provided the foundational DNA that allowed Biogen to eventually pivot and dominate the treatment of multiple sclerosis.
Ken Murray, Phillip Sharp, Walter Gilbert, and Charles Weissmann founded Biogen in Geneva, Switzerland, with the explicit vision of applying recombinant DNA technology to the development of novel human therapeutics, establishing the foundational business model of scalable, reliable biologic manufacturing.
Biogen completed its initial public offering, raising significant capital to fund the expansion of its global manufacturing footprint and the acceleration of its R&D pipeline in recombinant DNA therapies.
The FDA approved Avonex (interferon beta-1a) for the treatment of relapsing forms of multiple sclerosis, establishing the organization's leadership in the neurotherapeutics market and generating billions of dollars in annual revenue.
The FDA approved Tysabri (natalizumab) for the treatment of multiple sclerosis, representing a major breakthrough in neurology and a potential blockbuster asset for the organization, though it was later temporarily withdrawn due to safety concerns.
The organization entered into a strategic partnership with Ionis Pharmaceuticals to develop and commercialize Spinraza (nusinersen) for spinal muscular atrophy, securing exclusive rights to the first FDA-approved therapy for this devastating rare disease.
The FDA approved Aduhelm (aducanumab) for Alzheimer's disease despite strong opposition from its own advisory committee, sparking intense regulatory scrutiny and reputational damage that ultimately led to the discontinuation of the program.
The FDA approved Skyclarys (omaveloxolone) for the treatment of Friedreich's ataxia, representing a major breakthrough in rare neurology and a potential blockbuster asset for the organization.
The FDA granted full approval to Leqembi (lecanemab) for the treatment of early Alzheimer's disease, in a strategic partnership with Eisai, establishing the organization's leadership in the neurodegeneration market.
The organization reported consolidated net revenues of $9.62 billion for FY2024, with the Pharmaceuticals division contributing the vast majority of this total through the sale of high-margin biologics, small molecules, and targeted therapies, while allocating approximately $3.24 billion to research and development.
Christopher Viehbacher assumed the role of Chief Executive Officer in November 2022, bringing deep industry experience and a renewed focus on operational excellence and pipeline innovation.
The organization entered into a strategic partnership with Eisai to co-develop and co-commercialize Leqembi for Alzheimer's disease, securing exclusive rights to the anti-amyloid monoclonal antibody in the US and select other markets.
The organization entered into a strategic partnership with Ionis Pharmaceuticals to develop and commercialize Spinraza for spinal muscular atrophy, securing exclusive rights to the first FDA-approved therapy for this devastating rare disease.
The organization internally developed Skyclarys for the treatment of Friedreich's ataxia, securing exclusive rights to the first FDA-approved therapy for this devastating rare neurological disorder.
Since its establishment in 1978, Biogen Inc. expanded from an early-stage venture into a recognized leader in Biotechnology and Pharmaceuticals, overcoming key market challenges.
Over its history, Biogen Inc. executed decisive strategic pivots toward scalable monetization and digital distribution, securing its current market leadership.
By continually modernizing operations and embracing workflow automation, Biogen Inc. maintains resilience through changing technological and economic cycles.